Egypt's EDA Wins WHO Prequalification for Drug Quality Control Labs, Cementing Maturity Level 3 Status
核心洞察
Egypt's drug regulator secured WHO prequalification for its pharmaceutical quality control laboratories, the first Egyptian regulatory labs to earn the designation.
The EDA already holds WHO Maturity Level 3 for both medicines and vaccines, making Egypt the first African country to reach that milestone in both fields.
Prime Minister Mostafa Madbouly met EDA Chairman Ali El-Ghamrawy to review progress toward WHO Maturity Level 4 accreditation.
Egypt's pharmaceutical regulatory system has secured a new international benchmark, with the World Health Organization granting prequalification to the Egyptian Drug Authority (搜索)'s pharmaceutical quality control laboratories — the first Egyptian regulatory laboratories to receive the designation.
The achievement followed the laboratories' successful completion of a series of tests, assessment visits and inspections conducted by the WHO, according to EDA spokesperson Yassin Ragai, who announced the milestone in a phone-in interview with Hatha Al-Sabah (This Morning) on Extra News TV.
Ragai said the prequalification reflects the efficiency of Egypt's regulatory system and the compliance of EDA procedures with international standards, strengthening confidence in the country's pharmaceutical quality control capabilities. He added that it enhances Egypt's ability to participate in medicine quality assessment systems used by international agencies and organizations, and strengthens its role in decision-making on the quality, safety and efficacy of medicines.
A Regulatory Track Record in Africa
The laboratory accreditation adds to a series of international milestones for the EDA. The authority previously attained WHO Maturity Level 3 for vaccines in March 2022 and has now reached the same level for medicines, making Egypt the first country in Africa to achieve the milestone in both fields.
According to EDA Chairman Ali El-Ghamrawy, WHO's continued recognition of Egypt's regulatory system at Maturity Level 3 reflects the efficiency, stability and integration of the regulatory framework and its ability to perform its functions in line with international standards. He said the recognition consolidates Egypt's leadership at the Arab and African levels and strengthens its role in shaping the global pharmaceutical landscape, including through more effective participation in developing global pharmaceutical policies and standards.
Ragai also noted that Egypt has been designated a training center for biopharmaceutical manufacturing, alongside the authority's ongoing work to fulfill requirements for Maturity Level 4.
Prime Minister Reviews Path to Maturity Level 4
Prime Minister Mostafa Madbouly discussed the developments with El-Ghamrawy during a meeting on Sunday, September 13, 2026, to review the authority's work files and efforts to develop Egypt's pharmaceutical system.
El-Ghamrawy said the EDA is continuing work on improvements and upgrades required to advance to WHO-accredited Maturity Level 4. He reviewed key findings from the WHO's assessment visit, which showed higher levels of implementation across the authority's various regulatory functions and areas of responsibility, and affirmed that Egypt is proceeding along the normal course of WHO reassessment processes to support continuous improvement and sustainability of the maturity level achieved.
Madbouly congratulated El-Ghamrawy and EDA employees on the achievement, describing the continued attainment of Maturity Level 3 for medicines alongside the same level for vaccines as a global achievement reflecting the progress of Egypt's pharmaceutical system and the ability of state institutions to meet leading international standards. He stressed the importance of preserving the gains achieved and advancing toward higher levels of international recognition.
Industrial and Market Implications
The prime minister underscored the need to continue efforts to strengthen Egypt's domestic pharmaceutical industry, support localization of pharmaceutical and medical-supplies production, and increase local output to help secure market needs, reduce reliance on imports and open new prospects for Egyptian pharmaceutical exports — while maintaining the highest standards of quality and efficacy. He described the pharmaceutical sector as one of the vital sectors receiving significant state attention given its direct role in meeting citizens' essential needs.
Ragai said greater international recognition of Egypt's regulatory capabilities would help boost public confidence in Egyptian medicines, enhance their reputation and facilitate their access to global markets. He stressed that the EDA now has the capabilities to assess locally produced and imported medicines, including products from reference countries, and to serve as a reference regulatory authority in evaluating their quality, suitability and availability in the Egyptian market — further strengthening Egypt's presence in Africa and internationally.
Ensuring the safety, efficacy and quality of pharmaceutical products remains among the EDA's key regulatory responsibilities, Ragai said.